"FARA has been working with Retrotope for the past few years as RT001 has gone through pre-clinical development and we believe this provides an excellent example of the power of patient engagement early in the drug development process. FARA provided assistance in developing partnerships with academic collaborators who have tested RT001 in FA cellular models, grant support for manufacturing, attendance at regulatory meetings and engagement of the patient community in focus group discussions on diet modifications recommended for this early phase study. We are excited to continue our partnership and support as we approach this new and important milestone," said Jennifer Farmer, MS, CGC, Executive Director at FARA.

Two of FARA's Collaborative Clinical Research Network sites, the University of South Florida and the University of California Los Angeles, will be conducting the study and FARA will utilize the Patient Registry to assist the sites in recruitment. The University of South Florida is open for enrollment, the University of California Los Angeles will be opening in the early fall for enrollment.

Click here for the USF study recruitment notice.

Read more: Retrotope announces open enrollment for Friedreich's ataxia clinical trial